EUVIMEDEUVIMED entdecken
Open Access

Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease

Lauren V Collen, Vanessa Mitsialis, David Y Kim, Mairead Bresnahan, Jessica Yang, Margaret Tuthill, Abigail Combs, Jared Barends, Michael Field, Enju Liu iD, Richelle Bearup, Ibeawuchi Okoroafor und 5 weitere

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Lauren V Collen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA,…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Tumor Necrosis Factor-alpha, Age of Onset. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institute of Diabetes and Digestive Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Very early onset inflammatory bowel disease (VEOIBD) is defined as disease onset in patients younger than 6 years. Challenges in treatment of VEOIBD include lack of approved therapies and increased incidence of monogenic immunodeficiencies. We report on patterns of anti-TNF use, efficacy, and safety in a large cohort of patients with VEOIBD.

Methods

Very early onset inflammatory bowel disease patients receiving care at a single center were prospectively enrolled in a data registry and biorepository starting in 2012. Whole exome sequencing was available to all patients. Clinical data including IBD medication use and response were extracted from the medical record. We examined antitumor necrosis factor (anti-TNF) cumulative exposure and time to failure and evaluated the effect of covariates on anti-TNF failure using Cox proportional hazard regression.

Results

In this cohort of 216 VEOIBD patients with median 5.8-year follow-up, 116 (53.7%) were TNF-exposed. Sixty-two TNF-exposed patients (53.4%) received their first dose at younger than 6 years. Cumulative exposure to anti-TNF was 23.6% at 1 year, 38.4% at 3 years, and 43.4% at 5 years after diagnosis. Cumulative exposure was greater in patients with Crohn’s disease (P = .0004) and in those diagnosed in 2012 or later (P < .0001). Tumor necrosis factor failure occurred in 50.9% of those exposed. Features predictive of anti-TNF failure included ulcerative colitis/IBD-unclassified (hazard ratio, 1.94; P = .03), stricturing (hazard ratio, 2.20; P = .04), and younger age at diagnosis (hazard ratio, 1.25; P = .01). Adverse events occurred in 22.6% of infliximab-exposed and 14.3% of adalimumab-exposed.

Conclusions

Efficacy and safety of anti-TNFs in VEOIBD is comparable to what has previously been reported in older patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesTumor Necrosis Factor-alphaAge of OnsetHumansFemaleMaleProspective StudiesChild, PreschoolInfantChildFollow-Up StudiesAdalimumabProportional Hazards ModelsInfliximabRegistriesGastrointestinal AgentsTreatment Outcome

Stichwörter der Autor:innen

adalimumabinfliximabmonogenicvery early onset inflammatory bowel diseasewhole exome sequencing

Substanzen

Tumor Necrosis Factor-alphaAdalimumabInfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Division of Gastroenterology, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, 02115, USA.
  • Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU Klinikum, and Gene Center, Ludwig Maximilians Universität München, Germany.
  • SickKids Inflammatory Bowel Disease Center, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Enju Liu, Jodie Ouahed, Scott B Snapper

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institute of Diabetes and Digestive Kidney Diseases
  • National Institutes of Health

Zitieren

APA

Collen, L. V., Mitsialis, V., Kim, D. Y., Bresnahan, M., Yang, J., Tuthill, M., Combs, A., Barends, J., Field, M., Liu, E., Bearup, R., Okoroafor, I., Klein, C., Muise, A. M., Bousvaros, A., Ouahed, J., & Snapper, S. B. (2024). Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad196

Vancouver

Collen LV, Mitsialis V, Kim DY, Bresnahan M, Yang J, Tuthill M, et al. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad196

BibTeX
@article{Collen2024,
  author = {Collen, Lauren V and Mitsialis, Vanessa and Kim, David Y and Bresnahan, Mairead and Yang, Jessica and Tuthill, Margaret and Combs, Abigail and Barends, Jared and Field, Michael and Liu, Enju and Bearup, Richelle and Okoroafor, Ibeawuchi and Klein, Christoph and Muise, Aleixo M and Bousvaros, Athos and Ouahed, Jodie and Snapper, Scott B},
  title = {Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad196}
}
Kostenlos starten →